Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 10/20 | 0.49 |
| ▸ | LIPG | Q9Y5X9 | 10/20 | 0.49 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | P4HB | P07237 | 1/20 | 0.35 |
| ▸ | CSF1R | P07333 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16837490 | 0.89 | LIPG (0.54) | LPLLIPGPRMT5WDR77IDO1 | |
| SCHEMBL12126755 | 0.89 | LIPG (0.47) | LPLLIPGPRMT5WDR77EGFR | |
| SCHEMBL311849 | 0.87 | LPL (0.56) | LPLLIPGPRMT5WDR77EGFR | |
| SCHEMBL2015694 | 0.87 | LPL (0.56) | LPLLIPGPRMT5WDR77EGFR | |
| SCHEMBL21764502 | 0.87 | LPL (0.56) | LPLLIPGPRMT5WDR77EGFR | |
| SCHEMBL29787170 | 0.87 | LPL (0.56) | LPLLIPGPRMT5WDR77EGFR | |
| SCHEMBL17548647 | 0.87 | LPL (0.56) | LPLLIPGPRMT5WDR77EGFR | |
| SCHEMBL15456760 | 0.87 | LPL (0.56) | LPLLIPGPRMT5WDR77EGFR | |
| SCHEMBL16837492 | 0.87 | LIPG (0.53) | LPLLIPGPRMT5WDR77IDO1 | |
| SCHEMBL25822924 | 0.87 | LPL (0.49) | LPLLIPGPRMT5WDR77EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580400-B2 | Bichrysene compound and organic light emitting device having the compound | CANON KABUSHIKI KAISHA (JP) | 2013-11-12 | — | — | US | disclosed |
| US-8580400-B2 | Bichrysene compound and organic light emitting device having the compound | CANON KABUSHIKI KAISHA (JP) | 2013-11-12 | — | — | US | disclosed |
| US-20110272683-A1 | NOVEL BICHRYSENE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE HAVING THE COMPOUND | CANON KABUSHIKI KAISHA (JP) | 2011-11-10 | — | — | US | disclosed |
| US-20110272683-A1 | NOVEL BICHRYSENE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE HAVING THE COMPOUND | CANON KABUSHIKI KAISHA (JP) | 2011-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110272683-A1 | NOVEL BICHRYSENE COMPOUND AND ORGANIC LIGHT EMITTING DEVICE HAVING THE COMPOUND | PPOX, CRY1, OXER1 | LPL 2855/4885LIPG 3410/4885PRMT5 4674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.